International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study
Caron A, van Huizen A, Musters A, Gerbens L, Middelkamp Hup M, Flohr C, Irvine A, Vestergaard C, Peris K, Brandling-Bennett H, Drucker A, Spuls P
J EUR ACAD DERMATOL. 2025;39(2):331-339.

Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis
Gooderham M, Ameen M, Hong H, Katoh N, Langley R, Peris K, Reich K, Silvestre J, Simpson E, Werfel T, Gjerum L, Tindberg A, Øland C, Blauvelt A
J EUR ACAD DERMATOL. 2025 [Epub ahead of print].

Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial
McInnes I, Coates L, Mease P, Ogdie A, Kavanaugh A, Eder L, Schett G, Kivitz A, McGonagle D, Brennan N, Godwood A, Cullen E, Reich K, Ritchlin C, Merola J
NAT MED. 2025;31(12):4160-4171.

Lessons from TNF-α Inhibitor-Induced Alopecia Areata: Does TNF-α Operate as a Hair Follicle Immune Privilege Guardian under Inflammatory Conditions?
Perez S, Kabashima K, Reich K, Gilliet M, Gilhar A, Paus R
J INVEST DERMATOL. 2025;145(10):2410-2416.e3.

Favourable response of Blaschko linear psoriasis to interleukin-23 inhibition
Reich J, Onoufriadis A, McGrath J, Reich K
Skin health and disease. 2025;5(1):82-87.

Effects of a Gel Containing the Defined Microalgae Extract Spiralin® on the Skin Microbiome and Clinical Activity in Atopic Dermatitis: A Double-Blind, Intraindividual Vehicle-Controlled Proof-Of-Concept Study
Reich K, Trettel N, Reich J, Sorbe C, Bickert T, Hartmann J, Harder I, Gerdes S, Weidinger S
SKIN PHARMACOL PHYS. 2025;38(5-6):232-236.

Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial
Eyerich K, Asadullah K, Pinter A, Weisenseel P, Reich K, Paul C, Sabat R, Wolk K, Eyerich S, Lauffer F, Angsana J, Taut F, Kohler K, Chen Y, Sendecki J, Leung M, Wegner S, Personke Y, Gomez M, Krüger N, Tabori S, Schäkel K
JAMA DERMATOL. 2024;160(9):953-963.

Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years
Guttman-Yassky E, Kabashima K, Staumont-Salle D, Nahm W, Pauser S, Da Rosa J, Martel B, Madsen D, Røpke M, Arlert P, Steffensen L, Blauvelt A, Reich K
ALLERGY. 2024;79(6):1560-1572.

Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study
Guttman-Yassky E, Simpson E, Reich K, Kabashima K, Igawa K, Suzuki T, Mano H, Matsui T, Esfandiari E, Furue M
ADV THER. 2024;41(3):928-931.

Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape
Krueger J, Frew J, Jemec G, Kimball A, Kirby B, Bechara F, Navrazhina K, Prens E, Reich K, Cullen E, Wolk K
BRIT J DERMATOL. 2024;190(2):149-162.

SARS-CoV-2 infection among psoriasis patients in Germany: Data from the German registries PsoBest and CoronaBest
López M, Meineke A, Stephan B, Rustenbach S, Kis A, Thaçi D, Mrowietz U, Reich K, Staubach-Renz P, von Kiedrowski R, Bogena H, Augustin M
J DTSCH DERMATOL GES. 2024;22(7):965-972.

Patient and physician outcomes of a store-and-forward teledermatology application in Germany
Otten M, Greis C, Reinders P, Fleyder A, Reich K, Augustin M
J EUR ACAD DERMATOL. 2024;38(2):e148-e151.

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
Reich K, Bianchi L, Khemis A, Maul J, Tsianakas A, Schempp C, Petersen K, Noergaard M, Puig L
DERMATOLOGY THER. 2024;14(2):453-468.

Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries
Valencia López M, Stephan B, Meineke A, Wolf S, Thaci D, Mrowietz U, Andrees V, Rustenbach S, Reich K, Thalmann L, Bogena H, Staubach P, von Kiedrowski R, Augustin M
PSORIASIS-TARGETS TH. 2024;14:29-38.

Gene Expression-Based Molecular Test as Diagnostic Aid for the Differential Diagnosis of Psoriasis and Eczema in Formalin-Fixed and Paraffin-Embedded Tissue, Microbiopsies, and Tape Strips
Fischer F, Doll A, Uereyener D, Roenneberg S, Hillig C, Weber L, Hackert V, Meinel M, Farnoud A, Seiringer P, Thomas J, Anand P, Graner L, Schlenker F, Zengerle R, Jonsson P, Jargosch M, Theis F, Schmidt-Weber C, Biedermann T, Howell M, Reich K, Eyerich K, Menden M, Garzorz-Stark N, Lauffer F, Eyerich S
J INVEST DERMATOL. 2023;143(8):1461-1469.e5.

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis:a multicentre, double-blind, placebo-controlled phase 2b study
Guttman-Yassky E, Simpson E, Reich K, Kabashima K, Igawa K, Suzuki T, Mano H, Matsui T, Esfandiari E, Furue M
LANCET. 2023;401(10372):204-214.

Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply
Guttman-Yassky E, Simpson E, Reich K, Kabashima K, Igawa K, Suzuki T, Mano H, Matsui T, Esfandiari E, Furue M
LANCET. 2023;402(10415):1834.

Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations
Jo S, Huang Y, Tsai T, Kim B, Reich K, Saadoun C, Chang C, Yang Y, Youn S
J DERMATOL. 2023;50(9):1180-1189.

Open-Label Observational Study of a Topical Formulation of Calcium Spirulan Contained in a Defined Extract of the Microalga Spirulina platensis in the Treatment of Children with Molluscum Contagiosum
Jungclaus K, Mascarenhas R, Tellechea O, Reich J, Reich K
DERMAT RES PRACT. 2023;2023:.

Autologous Th2-polarized lymphocytes induce atopic dermatitis lesions in non-atopic human skin xenotransplants
Keren A, Reich K, Bertolini M, Moga A, Riethmüller C, Ullmann Y, Paus R, Gilhar A
ALLERGY. 2023;78(6):1538-1553.

Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2
Kim B, Jo S, Youn S, Reich K, Saadoun C, Chang C, Yang Y, Huang Y, Tsai T
DERMATOLOGY THER. 2023;13(11):2721-2737.

Secukinumab versus guselkumab in the complete resolution of ustekinumab-resistant psoriatic plaques: The ARROW study
Krueger J, Langley R, Nigen S, Kasparek T, Di Comite G, Ortmann C, Garcet S, Kolbinger F, Reich K
EXP DERMATOL. 2023;32(10):1834-1847.

Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials
Langley R, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren R, Paul C, Szepietowski J, Tsai T, Hampele I, You R, Charef P, Papavassilis C
BRIT J DERMATOL. 2023;188(2):198-207.

Methods used for indirect comparisons of systemic treatments for psoriasis: A systematic review
Nast A, Dressler C, Schuster C, Saure D, Augustin M, Reich K
Skin health and disease. 2023;3(1):.

Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study
Papp K, Warren R, Green L, Reich K, Langley R, Paul C, Asahina A, Johnson L, Arora V, Osuntokun O, Lebwohl M
LANCET RHEUMATOL. 2023;5(9):e542-e552.

Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study
Reich K, Silverberg J, Papp K, Deleuran M, Katoh N, Strober B, Beck L, de Bruin-Weller M, Werfel T, Zhang F, Biswas P, DiBonaventura M, Chan G, Farooqui S, Kerkmann U, Clibborn C
J EUR ACAD DERMATOL. 2023;37(10):2047-2055.

Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study
Reich K, Silverberg J, Papp K, Deleuran M, Katoh N, Strober B, Beck L, de Bruin-Weller M, Werfel T, Zhang F, Biswas P, DiBonaventura M, Chan G, Johnson S, Farooqui S, Kerkmann U, Clibborn C
J EUR ACAD DERMATOL. 2023;37(10):2056-2066.

Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3
Reich K, Simpson E, Wollenberg A, Bissonnette R, Abe M, Cardillo T, Janes J, Sun L, Chen S, Silverberg J
BRIT J DERMATOL. 2023;188(2):208-217.

Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms
Reich K, Thyssen J, Blauvelt A, Eyerich K, Soong W, Rice Z, Hong H, Katoh N, Valenzuela F, DiBonaventura M, Bratt T, Zhang F, Clibborn C, Rojo R, Valdez H, Kerkmann U
IMMUNOTHERAPY-UK. 2023;15(13):975-980.

Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study
Schäkel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P, Paul C, Gomez M, Wegner S, Personke Y, Kreimendahl F, Chen Y, Angsana J, Leung M, Eyerich K
J EUR ACAD DERMATOL. 2023;37(10):2016-2027.

Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis
Signorovitch J, Diels J, Van Sanden S, Schubert A, Hassan F, Thilakarathne P, Ozturk B, Barthelmes N, Reich K
J DERMATOL TREAT. 2023;34(1):.

Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids
Silverberg J, Armstrong A, Blauvelt A, Reich K
AM J CLIN DERMATOL. 2023;24(6):913-925.

SARS-CoV-2 vaccination status and adverse events among patients with psoriasis-Data from the German Registries PsoBest and CoronaBest
Valencia López M, Meineke A, Stephan B, Rustenbach S, Kis A, Thaçi D, Mrowietz U, Reich K, Staubach-Renz P, von Kiedrowski R, Bogena H, Augustin M
J EUR ACAD DERMATOL. 2023;37(7):e831-e833.

Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment
Wolk K, Wilsmann-Theis D, Witte K, Brembach T, Kromer C, Gerdes S, Ghoreschi K, Reich K, Mössner R, Sabat R
INT J MOL SCI. 2023;24(2):1276.

Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab
Augustin M, Gallo G, See K, McKean-Matthews M, Burge R, Gooderham M, Reich K
J DRUGS DERMATOL. 2022;21(2):122-126.

Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial
Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D
BRIT J DERMATOL. 2022;186(6):942-954.

Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4)
Bieber T, Reich K, Paul C, Tsunemi Y, Augustin M, Lacour J, Ghislain P, Dutronc Y, Liao R, Yang F, Brinker D, DeLozier A, Meskimen E, Janes J, Eyerich K
BRIT J DERMATOL. 2022;187(3):338-352.

Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
Blauvelt A, Armstrong A, Langley R, Gebauer K, Thaçi D, Bagel J, Guenther L, Paul C, Randazzo B, Flavin S, Hsu M, You Y, Reich K
J DERMATOL TREAT. 2022;33(4):2317-2324.

Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
Blauvelt A, Langley R, Lacour J, Toth D, Laquer V, Beissert S, Wollenberg A, Herranz P, Pink A, Peris K, Fangel S, Gjerum L, Corriveau J, Saeki H, Warren R, Simpson E, Reich K
J AM ACAD DERMATOL. 2022;87(4):815-824.

Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form
Blome C, von Stülpnagel C, Augustin M, Mrowietz U, Reich K, Muehlan H, Kirsten N, Langenbruch A, Sorbe C, Klein T
BRIT J DERMATOL. 2022;187(4):588-589.

Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis
Conrad C, Ortmann C, Vandemeulebroecke M, Kasparek T, Reich K
DERMATOLOGY THER. 2022;12(1):233-241.

Contact sensitization to essential oils:IVDK data of the years 2010-2019
Geier J, Schubert S, Reich K, Skudlik C, Ballmer-Weber B, Brehler R, Weisshaar E, Uter W
CONTACT DERMATITIS. 2022;87(1):71-80.

Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis
Gordon K, Lebwohl M, Papp K, Bachelez H, Wu J, Langley R, Blauvelt A, Kaplan B, Shah M, Zhao Y, Sinvhal R, Reich K
BRIT J DERMATOL. 2022;186(3):466-475.

Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials
Gordon K, Reich K, Crowley J, Korman N, Murphy F, Poulin Y, Spelman L, Yamauchi P, Mendelsohn A, Parno J, Rozzo S, Ellis C
J DERMATOL TREAT. 2022;33(1):219-228.

Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey
Lebwohl M, Langley R, Paul C, Puíg L, Reich K, van de Kerkhof P, Wu H, Richter S, Jardon S, Gisondi P
DERMATOLOGY THER. 2022;12(1):61-78.

Tepilamide Fumarate (PPC-06) Extended Release Tablets in Patients with Moderate-to-Severe Plaque Psoriasis: Safety and Efficacy Results from the Randomized, Double-blind, Placebo-controlled AFFIRM Study
Mrowietz U, Kircik L, Reich K, Munjal S, Shenoy S, Lebwohl M
The Journal of clinical and aesthetic dermatology. 2022;15(1):53-58.

Transcriptomic Analysis of Blaschko-Linear Psoriasis Reveals Shared and Distinct Features with Psoriasis Vulgaris
Onoufriadis A, Niazi U, Dimitrakopoulou K, Reich J, Ainali C, Papanikolaou M, Kesidou E, Hsu C, Saqi M, McGrath J, Reich K
J INVEST DERMATOL. 2022;142(2):489-493.

Generalized pustular psoriasis: overview of the status quo and results of a panel discussion
Reich K, Augustin M, Gerdes S, Ghoreschi K, Kokolakis G, Mößner R, Mrowietz U, Navarini A, Pinter A, Schäkel K, Staubach P, Sticherling M, Thaçi D, Wilsmann-Theis D
J DTSCH DERMATOL GES. 2022;20(6):753-771.

Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis
Reich K, Baraliakos X, Coates L, Elewski B, Bao W, Kasparek T, Gaillez C, Pournara E, Aassi M, Perella C, Gottlieb A
BRIT J DERMATOL. 2022;187(3):438-441.

Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis
Reich K, Conrad C, Kristensen L, Smith S, Puig L, Rich P, Sapin C, Holzkaemper T, Koppelhus U, Schuster C
J DERMATOL TREAT. 2022;33(3):1652-1660.

Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence?
Reich K, Cullen E, Weinberg M
BRIT J DERMATOL. 2022;187(4):591-593.

Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials
Reich K, DeLozier A, Nunes F, Thyssen J, Eichenfield L, Wollenberg A, Ross Terres J, Watts S, Chen Y, Simpson E, Silverberg J
J DERMATOL TREAT. 2022;33(3):1521-1530 .

Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance
Reich K, Gordon K, Strober B, Langley R, Miller M, Yang Y, Shen Y, You Y, Zhu Y, Foley P, Blauvelt A
J EUR ACAD DERMATOL. 2022;36(12):2393-2400.

Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3
Reich K, Iversen L, Puig L, Lambert J, Mrowietz U, Kaplan Saday K, Warren R
J EUR ACAD DERMATOL. 2022;36(8):1275-1283.

Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO
Reich K, Korge B, Magnolo N, Manasterski M, Schwichtenberg U, Staubach-Renz P, Kaiser S, Roemmler-Zehrer J, Gómez N, Lorenz-Baath K
DERMATOLOGY THER. 2022;12(1):203-221.

Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial
Reich K, Kristensen L, Smith S, Rich P, Sapin C, Leage S, McKenzie R, Schuster C, Riedl E, Gooderham M
DERMATOL PRACT CONCE. 2022;12(2):.

Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis
Reich K, Lio P, Bissonnette R, Alexis A, Lebwohl M, Pink A, Kabashima K, Boguniewicz M, Nowicki R, Valdez H, Zhang F, DiBonaventura M, Cameron M, Clibborn C
J ALLER CL IMM-PRACT. 2022;10(12):3228-3237.e2.

Response to fumaric acid esters for plaque type psoriasis in real-world practice is largely independent of patient characteristics at baseline - a multivariable regression analysis from the German Psoriasis Registry PsoBest
Reich K, Mrowietz U, Sorbe C, von Kiedrowski R, Diemert S, Schaeffer L, Kirsten N, Ben-Anaya N, Augustin M
J DERMATOL TREAT. 2022;33(8):3170-3177.

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial
Reich K, Thyssen J, Blauvelt A, Eyerich K, Soong W, Rice Z, Hong H, Katoh N, Valenzuela F, DiBonaventura M, Bratt T, Zhang F, Clibborn C, Rojo R, Valdez H, Kerkmann U
LANCET. 2022;400(10348):273-282.

Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results
Silverberg J, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Costanzo A, Rosmarin D, Lynde C, Liu J, Gamelli A, Zeng J, Ladizinski B, Chu A, Reich K
J ALLERGY CLIN IMMUN. 2022;149(3):977-987.e14.

Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis
Silverberg J, Simpson E, Armstrong A, de Bruin-Weller M, Irvine A, Reich K
AM J CLIN DERMATOL. 2022;23(1):1-11.

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis
Simpson E, Bissonnette R, Paller A, King B, Silverberg J, Reich K, Thyssen J, Doll H, Sun L, DeLozier A, Nunes F, Eichenfield L
BRIT J DERMATOL. 2022;187(4):531-538.

Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
Simpson E, Merola J, Silverberg J, Reich K, Warren R, Staumont-Sallé D, Girolomoni G, Papp K, de Bruin-Weller M, Thyssen J, Zachariae R, Olsen C, Wollenberg A
BRIT J DERMATOL. 2022;187(6):888-899.

The hair follicle-psoriasis axis: Shared regulatory mechanisms and therapeutic targets
Suzuki T, Ito T, Gilhar A, Tokura Y, Reich K, Paus R
EXP DERMATOL. 2022;31(3):266-279.

Molecular diagnostics in dermatology
Tizek L, Schuster B, Gebhardt C, Reich K, von Kiedrowski R, Biedermann T, Eyerich K, Zink A, Garzorz-Stark N
J DTSCH DERMATOL GES. 2022;20(3):287-295.

International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis
van Huizen A, Menting S, Gyulai R, Iversen L, van der Kraaij G, Middelkamp-Hup M, Warren R, Spuls P
JAMA DERMATOL. 2022;158(5):561-572.

Network meta-analyses in psoriasis: overview and critical discussion
Augustin M, Valencia López M, Reich K
J EUR ACAD DERMATOL. 2021;35(12):2367-2376.

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
Bieber T, Thyssen J, Reich K, Simpson E, Katoh N, Torrelo A, De Bruin-Weller M, Thaci D, Bissonnette R, Gooderham M, Weisman J, Nunes F, Brinker D, Issa M, Holzwarth K, Gamalo M, Riedl E, Janes J
J EUR ACAD DERMATOL. 2021;35(2):476-485.

Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies
Blauvelt A, Paul C, van de Kerkhof P, Warren R, Gottlieb A, Langley R, Brock F, Arendt C, Boehnlein M, Lebwohl M, Reich K
BRIT J DERMATOL. 2021;184(4):640-651.

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
Eyerich K, Weisenseel P, Pinter A, Schäkel K, Asadullah K, Wegner S, Muñoz-Elias E, Bartz H, Taut F, Reich K
BMJ OPEN. 2021;11(9):.

Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis
Fahrbach K, Sarri G, Phillippo D, Neupane B, Martel S, Kiri S, Reich K
DERMATOLOGY THER. 2021;11(6):1965-1998.

Mouse models of atopic dermatitis: a critical reappraisal
Gilhar A, Reich K, Keren A, Kabashima K, Steinhoff M, Paus R
EXP DERMATOL. 2021;30(3):319-336.

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
Gordon K, Foley P, Krueger J, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A
LANCET. 2021;397(10273):475-486.

Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)
Gordon K, Warren R, Gottlieb A, Blauvelt A, Thaçi D, Leonardi C, Poulin Y, Boehnlein M, Brock F, Ecoffet C, Reich K
BRIT J DERMATOL. 2021;184(4):652-662.

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study
Gottlieb A, Merola J, Reich K, Behrens F, Nash P, Griffiths C, Bao W, Pellet P, Pricop L, McInnes I
BRIT J DERMATOL. 2021;185(6):1124-1134.

Which PASI Outcome Is Most Relevant to the Patients in Real-World Care?
Kirsten N, Rustenbach S, von Kiedrowski R, Sorbe C, Reich K, Augustin M
LIFE-BASEL. 2021;11(11):.

Quality of psoriasis care in Germany - results from the nationwide health care studies PsoHealth 2004-2017
Langenbruch A, Mohr N, Kirsten N, Reich K, von Kiedrowski R, Strömer K, Mrowietz U, Augustin M
J EUR ACAD DERMATOL. 2021;35(7):1536-1542.

Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment
Leutz A, Pinter A, Thaçi D, Augustin M, Schuster C, Fotiou K, Hundemer H, Saure D, Mrowietz U, Reich K
BRIT J DERMATOL. 2021;184(3):548-550.

Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study
Maul J, Augustin M, Sorbe C, Conrad C, Anzengruber F, Mrowietz U, Reich K, French L, Radtke M, Häusermann P, Maul L, Boehncke W, Thaçi D, Navarini A
BRIT J DERMATOL. 2021;185(6):1160-1168.

Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab
Mehta H, Mashiko S, Angsana J, Rubio M, Hsieh Y, Maari C, Reich K, Blauvelt A, Bissonnette R, Muñoz-Elías E, Sarfati M
J INVEST DERMATOL. 2021;141(7):1707-1718.e9.

Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study
Mrowietz U, Burden A, Pinter A, Reich K, Schäkel K, Baum P, Datsenko Y, Deng H, Padula S, Thoma C, Bissonnette R
DERMATOLOGY THER. 2021;11(2):571-585.

Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
Mrowietz U, Warren R, Leonardi C, Saure D, Petto H, Hartz S, Dossenbach M, Reich K
J EUR ACAD DERMATOL. 2021;35(5):1161-1175.

Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 1: Therapieziele und Therapieempfehlungen
Nast A, Altenburg A, Augustin M, Boehncke W, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels H, Philipp S, Reich K, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C
J DTSCH DERMATOL GES. 2021;19(6):934-951.

Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidität
Nast A, Altenburg A, Augustin M, Boehncke W, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels H, Philipp S, Reich K, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C
J DTSCH DERMATOL GES. 2021;19(7):1092-1117.

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations
Nast A, Smith C, Spuls P, Avila Valle G, Bata-Csörgö Z, Boonen H, De Jong E, Garcia-Doval I, Gisondi P, Kaur-Knudsen D, Mahil S, Mälkönen T, Maul J, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt K, Sator P, Schmitt-Egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C
J EUR ACAD DERMATOL. 2021;35(2):281-317.

IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study
Papp K, Weinberg M, Morris A, Reich K
LANCET. 2021;397(10284):1564-1575.

A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)
Pinter A, Hoffmann M, Reich K, Augustin M, Kaplan K, Gudjónsdóttir S, Delvin T, Mrowietz U
J EUR ACAD DERMATOL. 2021;35(3):701-711.

Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2
Reich K, Gordon K, Strober B, Armstrong A, Miller M, Shen Y, You Y, Han C, Yang Y, Foley P, Griffiths C
BRIT J DERMATOL. 2021;185(6):1146-1159.

Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3
Reich K, Hansen J, Puig L, Konstantinou M, Warren R
J EUR ACAD DERMATOL. 2021;35(10):2034-2044.

Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study
Reich K, Körber A, Mrowietz U, Sticherling M, Sieder C, Früh J, Bachhuber T
BRIT J DERMATOL. 2021;184(5):849-856.

Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis
Reich K, Mrowietz U, Menter A, Griffiths C, Bagel J, Strober B, Nunez Gomez N, Shi R, Guerette B, Lebwohl M
J EUR ACAD DERMATOL. 2021;35(12):2409-2414.

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Reich K, Papp K, Blauvelt A, Langley R, Armstrong A, Warren R, Gordon K, Merola J, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M
LANCET. 2021;397(10273):487-498.

The value of subcutaneous vs. oral methotrexate: real-world data from the German psoriasis registry PsoBest
Reich K, Sorbe C, Griese L, Reich J, Augustin M
BRIT J DERMATOL. 2021;184(4):765-767.

Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study
Reich K, Sullivan J, Arenberger P, Jazayeri S, Mrowietz U, Augustin M, Elewski B, You R, Regnault P, Frueh J
BRIT J DERMATOL. 2021;184(3):425-436.

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
Reich K, Teixeira H, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Werfel T, Zeng J, Huang X, Hu X, Hendrickson B, Ladizinski B, Chu A, Silverberg J
LANCET. 2021;397(10290):2169-2181.

Bimekizumab versus Secukinumab in Plaque Psoriasis
Reich K, Warren R, Lebwohl M, Gooderham M, Strober B, Langley R, Paul C, De Cuyper D, Vanvoorden V, Madden C, Cioffi C, Peterson L, Blauvelt A
NEW ENGL J MED. 2021;385(2):142-152.

Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials
Silverberg J, Simpson E, Wollenberg A, Bissonnette R, Kabashima K, DeLozier A, Sun L, Cardillo T, Nunes F, Reich K
JAMA DERMATOL. 2021;157(6):691-699.

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)
Thaci D, Piaserico S, Warren R, Gupta A, Cantrell W, Draelos Z, Foley P, Igarashi A, Langley R, Asahina A, Young M, Falqués M, Pau-Charles I, Mendelsohn A, Rozzo S, Reich K
BRIT J DERMATOL. 2021;185(2):323-334.

Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach
Tsakok T, Rispens T, Spuls P, Nast A, Smith C, Reich K
J EUR ACAD DERMATOL. 2021;35(2):329-337.

Bimekizumab versus Adalimumab in Plaque Psoriasis
Warren R, Blauvelt A, Bagel J, Papp K, Yamauchi P, Armstrong A, Langley R, Vanvoorden V, De Cuyper D, Cioffi C, Peterson L, Cross N, Reich K
NEW ENGL J MED. 2021;385(2):130-141.

Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial
Warren R, Carrascosa J, Fumero E, Schoenenberger A, Lebwohl M, Szepietowski J, Reich K
J EUR ACAD DERMATOL. 2021;35(4):919-927.

Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3
Warren R, Hansen J, Reich K, Paul C, Puig L
J EUR ACAD DERMATOL. 2021;35(2):450-457.

A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS)
Wilsmann-Theis D, Kromer C, Gerdes S, Linker C, Magnolo N, Sabat R, Reich K, Mössner R
J EUR ACAD DERMATOL. 2021;35(10):2045-2050.

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
Armstrong A, Paul C, Puig L, Boehncke W, Freeman M, Torii H, Papp K, Griffiths C, Blauvelt A, Reich K, Gooderham M, Terui T, Renda L, Agada N, Xu W, Gallo G, Lebwohl M
DERMATOLOGY THER. 2020;10(1):133-150.

Continued treatment with secukinumab is associated with high retention or regain of response
Augustin M, Thaci D, Eyerich K, Pinter A, Radtke M, Lauffer F, Mrowietz U, Gerdes S, Pariser D, Lebwohl M, Sieder C, Melzer N, Reich K
BRIT J DERMATOL. 2020;182(1):67-75.

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial
Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon K, Ferris L, Langley R, Tada Y, Lima R, Elmaraghy H, Gallo G, Renda L, Park S, Burge R, Bagel J
BRIT J DERMATOL. 2020;182(6):1348-1358.

COVID‐19 und Auswirkungen auf dermatologische und allergologische Erkrankungen
Buhl T, Beissert S, Gaffal E, Goebeler M, Hertl M, Mauch C, Reich K, Schmidt E, Schön M, Sticherling M, Sunderkötter C, Traidl-Hoffmann C, Werfel T, Wilsman-Theis D, Worm M
J DTSCH DERMATOL GES. 2020;18(8):815-825.

Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care
da Silva N, Augustin M, Langenbruch A, Mrowietz U, Reich K, Thaçi D, Boehncke W, Kirsten N, Danckworth A, Sommer R
EUR J DERMATOL. 2020;30(3):267-278.

Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care
da Silva N, Augustin M, Langenbruch A, Mrowietz U, Reich K, Thaçi D, Boehncke W, Kirsten N, Danckworth A, Sommer R
PLOS ONE. 2020;15(7):.

Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
Deleuran M, Thaçi D, Beck L, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz J, Gelfand J, Sher L, Schuttelaar M, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis J, Rajadhyaksha M, Staudinger H, Graham N, Pirozzi G, Ardeleanu M
J AM ACAD DERMATOL. 2020;82(2):377-388.

Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial
Guttman-Yassky E, Thaçi D, Pangan A, Hong H, Papp K, Reich K, Beck L, Mohamed M, Othman A, Anderson J, Gu Y, Teixeira H, Silverberg J
J ALLERGY CLIN IMMUN. 2020;145(3):877-884.

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab
Kimball A, Kerbusch T, van Aarle F, Kulkarni P, Li Q, Blauvelt A, Papp K, Reich K, Montgomery D
BRIT J DERMATOL. 2020;182(1):180-189.

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies
Kimball A, Papp K, Reich K, Gooderham M, Li Q, Cichanowitz N, La Rosa C, Blauvelt A
BRIT J DERMATOL. 2020;182(6):1359-1368.

Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)
Lacour J, Bewley A, Hammond E, Hansen J, Horne L, Paul C, Reich K, Seneschal J, De Simone C, Sohrt A, Augustin M, Pellacani G
DERMATOLOGY THER. 2020;10(5):1099-1109.

Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis
Langley R, Reich K, Strand V, Feldman S, Paul C, Gordon K, Warren R, Toth D, Nikaï E, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin C, Hollister K, Augustin M
QUAL LIFE RES. 2020;29(2):369-380.

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
Leonardi C, Reich K, Foley P, Torii H, Gerdes S, Guenther L, Gooderham M, Ferris L, Griffiths C, ElMaraghy H, Crane H, Patel H, Burge R, Gallo G, Shrom D, Leung A, Lin C, Papp K
DERMATOLOGY THER. 2020;10(3):431-447.

Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care
Mrowietz U, Sorbe C, Reich K, Von Kiedrowski R, Weckbecker J, Radtke M, Rustenbach S, Augustin M
EUR J DERMATOL. 2020;30(1):41-48.

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations
Nast A, Smith C, Spuls P, Avila Valle G, Bata-Csörgö Z, Boonen H, De Jong E, Garcia-Doval I, Gisondi P, Kaur-Knudsen D, Mahil S, Mälkönen T, Maul J, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt K, Sator P, Schmitt-Egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C
J EUR ACAD DERMATOL. 2020;34(11):2461-2498.

A new treatment option for paediatric psoriasis
Reich K
BRIT J DERMATOL. 2020;183(4):606-607.

Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study
Reich K, Armstrong A, Foley P, Song M, Miller M, Shen Y, You Y, Han C, Gordon K
AM J CLIN DERMATOL. 2020;21(6):881-890.

A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment
Reich K, Augustin M, Thaçi D, Pinter A, Leutz A, Henneges C, Schneider E, Schacht A, Dossenbach M, Mrowietz U
BRIT J DERMATOL. 2020;182(4):869-879.

Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab
Reich K, Foley P, Han C, McElligott S, Muser E, Li N, Armstrong A
J DERMATOL TREAT. 2020;31(6):617-623.

Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials
Reich K, Griffiths C, Gordon K, Papp K, Song M, Randazzo B, Li S, Shen Y, Han C, Kimball A, Armstrong A, Foley P, Blauvelt A
J AM ACAD DERMATOL. 2020;82(4):936-945.

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial
Reich K, Kabashima K, Peris K, Silverberg J, Eichenfield L, Bieber T, Kaszuba A, Kolodsick J, Yang F, Gamalo M, Brinker D, DeLozier A, Janes J, Nunes F, Thyssen J, Simpson E
JAMA DERMATOL. 2020;156(12):1333-1343.

Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study
Reich K, Puig L, Szepietowski J, Paul C, Lacour J, Tsianakas A, Sieder C, Rissler M, Pournara E, Orsenigo R
BRIT J DERMATOL. 2020;182(2):304-315.

Long Term Efficacy and Safety of Secukinumab in the Treatment of the Multiple Manifestations of Psoriatic Disease
Reich K, Warren R, Coates L, Di Comite G
J EUR ACAD DERMATOL. 2020;34(6):1161-1173.

Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks
Reich K, Warren R, Iversen L, Puig L, Pau-Charles I, Igarashi A, Ohtsuki M, Falqués M, Harmut M, Rozzo S, Lebwohl M, Cantrell W, Blauvelt A, Thaçi D
BRIT J DERMATOL. 2020;182(3):605-617.

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)
Seneschal J, Lacour J, Bewley A, Faurby M, Paul C, Pellacani G, De Simone C, Horne L, Sohrt A, Augustin M, Hammond E, Reich K
J EUR ACAD DERMATOL. 2020;34(11):2566-2573.

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis
Simpson E, Bissonnette R, Eichenfield L, Guttman-Yassky E, King B, Silverberg J, Beck L, Bieber T, Reich K, Kabashima K, Seyger M, Siegfried E, Stingl G, Feldman S, Menter A, van de Kerkhof P, Yosipovitch G, Paul C, Martel P, Dubost-Brama A, Armstrong J, Chavda R, Frey S, Joubert Y, Milutinovic M, Parneix A, Teixeira H, Lin C, Sun L, Klekotka P, Nickoloff B, Dutronc Y, Mallbris L, Janes J, DeLozier A, Nunes F, Paller A
J AM ACAD DERMATOL. 2020;83(3):839-846.

Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
Simpson E, Lacour J, Spelman L, Galimberti R, Eichenfield L, Bissonnette R, King B, Thyssen J, Silverberg J, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman-Yassky E, Beck L, Janes J, DeLozier A, Gamalo M, Brinker D, Cardillo T, Nunes F, Paller A, Wollenberg A, Reich K
BRIT J DERMATOL. 2020;183(2):242-255.

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials
Blauvelt A, Sofen H, Papp K, Gooderham M, Tyring S, Zhao Y, Lowry S, Mendelsohn A, Parno J, Reich K
J EUR ACAD DERMATOL. 2019;33(12):2305-2312.

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing Spondylitis: integrated pooled clinical trial and post-marketing surveillance data
Deodhar A, Mease P, McInnes I, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T
ARTHRITIS RES THER. 2019;21(1):111.

Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study
Gordon K, Armstrong A, Foley P, Song M, Shen Y, Li S, Muñoz-Elías E, Branigan P, Liu X, Reich K
J INVEST DERMATOL. 2019;139(12):2437-2446.e1.

Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis
Lebwohl M, Langley R, Zhu Y, Zhou H, Song M, Shen Y, Parnell Lafferty K, Reich K
J EUR ACAD DERMATOL. 2019;33(11):2082-2086.

Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice
Maul J, Navarini A, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, Drach M, Blome C, Boehncke W, Thaci D, Reich K, von Kiedrowski R, Körber A, Yawalkar N, Mainetti C, Laffitte E, Streit M, Rustenbach S, Conrad C, Borradori L, Gilliet M, Cozzio A, Itin P, Häusermann P, French L, Radtke M, Augustin M
J EUR ACAD DERMATOL. 2019;33(4):700-708.

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
Reich K, Armstrong A, Langley R, Flavin S, Randazzo B, Li S, Hsu M, Branigan P, Blauvelt A
LANCET. 2019;394(10201):831-839.

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years
Reich K, Blauvelt A, Armstrong A, Langley R, de Vera A, Kolbinger F, Spindeldreher S, Ren M, Bruin G
J EUR ACAD DERMATOL. 2019;33(9):1733-1741.

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
Reich K, Gooderham M, Thaçi D, Crowley J, Ryan C, Krueger J, Tsai T, Flack M, Gu Y, Williams D, Thompson E, Paul C
LANCET. 2019;394(10198):576-586.

Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways
Reich K, Reich J, Falk T, Blödorn-Schlicht N, Mrowietz U, von Kiedrowski R, Pfeiffer C, Niesmann J, Frambach Y, Warren R
BRIT J DERMATOL. 2019;181(4):859-862.

Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2
Reich K, Song M, Li S, Jiang J, Youn S, Tsai T, Choe Y, Huang Y, Gordon K
J DERMATOL. 2019;46(12):1141-1152.

Measuring Patient Needs and Benefits in Dermatology using the Patient Benefit Index 2.0 - A Validation Study
Topp J, Augustin M, von Usslar K, Gosau R, Reich K, Reusch M, Blome C
ACTA DERM-VENEREOL. 2019;99(2):211-217.

Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis
Warren R, Barker J, Van de Kerkhof P, Reich K, Mrowietz U
J EUR ACAD DERMATOL. 2019;33(10):e352-e353.

Ulcerative keratitis in psoriasis: a rare variant of psoriatic ocular inflammatory disease
Herbert V, Lögering B, von Gruben V, Filev F, Klemm M, Reich K
BRIT J DERMATOL. 2014;170(3):746-8.

Letzte Aktualisierung aus dem FIS: 28.02.2026 - 00:33 Uhr